Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › belimumab

belimumab

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of belimumab

18 trials tracked of belimumab: 7 in phase 3 or 4 and 6 with published results. The most-cited published study has 111 citations.

18Trials tracked
7Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 8 Phase 1 3
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Completed · 111 cited
  2. Phase 3 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed · 86 cited
  3. Phase 3 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Completed · 42 cited
  4. Phase 3 Belimumab in Idiopathic Inflammatory Myositis Completed · 28 cited
  5. Phase 3 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Completed · 22 cited
  6. Phase 3 Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients Completed · 12 cited
Show 12 more trials
  1. Phase 4 Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE) Completed
  2. Phase 2 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed
  3. Phase 2 Rituximab and Belimumab for Lupus Nephritis Completed
  4. Phase 2 Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome Completed
  5. Phase 2 The Evaluation of Belimumab in Myasthenia Gravis (MG) Completed
  6. Phase 2 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis Completed
  7. Phase 2 A Study of Belimumab in the Prevention of Kidney Transplant Rejection Completed
  8. Phase 2 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies Completed
  9. Phase 2 A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 Completed
  10. Phase 1 A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus Completed
  11. Phase 1 Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation Completed
  12. Phase 1 Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids
Rheumatology Phase III
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids Trial shows belimumab improves remission rates for lupus patients
A post hoc analysis of phase III trials found that belimumab plus standard therapy led to higher rates of DORIS remission and LLDAS attainme…
A new analysis of clinical trials shows that the drug belimumab helps more people with lupus reach specific remission goals compared to a pl…
Jul 4, 2026
Belimumab plus standard therapy shows numerically greater reductions in IgA, IgM, and anti-dsDNA antibodies
Rheumatology RCT
Belimumab plus standard therapy shows numerically greater reductions in IgA, IgM, and anti-dsDNA antibodies Trial Shows Belimumab May Help Manage Lupus Nephritis Symptoms
This Phase 3 randomized controlled trial of 446 adults with active lupus nephritis found that intravenous belimumab plus standard therapy re…
A Phase 3 trial identifies specific markers that may help predict how patients with lupus nephritis respond to belimumab treatment.
Jul 4, 2026
Core set domains capture SLE treatment response in 89.5% of cases at week 52
Rheumatology RCT
Core set domains capture SLE treatment response in 89.5% of cases at week 52 Core set domains capture most lupus disease activity in a global trial
This phase III randomized controlled trial evaluated subjects with Systemic Lupus Erythematosus across a global setting. The study compared …
A global trial found that a core set of domains captured most lupus disease activity without missing important patient responses.
May 22, 2026
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
Infectious Disease Meta-analysis
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Frontiers May 2, 2026
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Rheumatology Meta-analysis
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
May 1, 2026